tbuckley/cabot-search huggingface dataset:
Prognostic Impact of Anthracycline Metabolism Gene Polymorphisms in Newly Diagnosed Acute Myeloid Leukemia Adults
Authors: Juan Eduardo Megías, Pau Montesinos, Marí­a José Herrero, Federico Moscardo, Virginia Bosó, David Martínez-Cuadrón, Luis Rojas, Rebeca Rodríguez-Veiga, Blanca Boluda, Jesus Martinez, Jaime Sanz, Francisca López, Isabel Cano, Carmen Alonso, Aima Lacharro, José Cervera, José Luis Poveda, Salvador Aliño, Miguel Ángel Sanz
Journal: Blood (2014)
Stem Cell Transplantation in Remission Improves Survival in Acute Myelogenous Leukemia Associated with FLT3 Mutations
Authors: Gautam Borthakur, Marcos de Lima, Hagop Kantarjian, Lianchun Xiao, Leandro de Padua Silva, Guillermo Garcia-Manero, Sergio Giralt, Farhad Ravandi-Kashani, Sherry Pierce, Richard Champlin
Journal: Blood (2008)
Carcinoembryonic-Antigen-Related Cell Adhesion Molecule (CEACAM) Expression on Multiple Myelomas Inhibits Their Recognition by Autologous Memory CD8 T Cells
Authors: Mathias Witzens-Harig, Dirk Hose, Michael Hundemer, Simone Jünger, Anthony D. Ho, Jean François Rossi, Kai Neben, Bernard Klein, Hartmut Goldschmidt, Philipp Beckhove
Journal: Blood (2008)
A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML
Authors: Abdullah Alsuliman, Muharrem Muftuoglu, Ahmad Khoder, Yong-Oon Ahn, Rafet Basar, Michael R. Verneris, Pawel Muranski, A. John Barrett, Enli Liu, Li Li, Kate Stringaris, Darius Armstrong-James, Hila Shaim, Kayo Kondo, Nobuhiko Imahashi, Borje Andersson, David Marin, Richard E. Champlin, Elizabeth J. Shpall, Katayoun Rezvani
Journal: Blood (2016)
O080 : Early clinical features associated with long-term risk of transplantation in primary sclerosing cholangitis: Results from the UK-PSC consortium
Authors: E.C. Goode, B. Srivastava, A.B. Clark, K. Spiess, G.M. Hirschfield, W.T.H. Gelson, P.J. Trivedi, G.F. Mells, R.N. Sandford, G.J. Alexander, R.W. Chapman, S.M. Rushbrook
Journal: Journal of Hepatology (2015)
AB0147 Study The Synchronous Effect of Intensive Care To Condition of Cardiovascular System in Patients with Systemic Lupus Erythematosus
Authors: E.R. Djurayeva, F.K. Ziyayeva, N.A. Ganiyeva, M.B. Kasymova, D.U. Berdiyeva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> To date, little is known about the pathogenesis, course and efficacy of cardiac complications of systemic lupus erythematosus (SLE), which requires the development of new therapies that allow to increase the life expectancy of patients. <h3>Objectives</h3> To study the effect of simultaneous intensive therapy on cardiovascular system in SLE. <h3>Methods</h3> The study involved 92 patients with SLE at the age of 18–55 years, with disease duration from 2 to 23 years. We analyzed the traditional cardiovascular risk factors, disease activity (SLEDAIK2, EKLAM). <h3>Results</h3> The vast majority of patients - 72 (78.6%) - revealed a subacute variant of the disease, and the average level of activity (80.2%). The classic cardiovascular risk factors were observed in 85 (92.3%) patients. Depending on the treatment options for the patients were divided into the following groups: I group - 32 patients received the classic three-day pulse therapy - metipred or Solu-Medrol 1000 mg/day and the second day of cyclophosphamide 1000 mg/day, against the background of glucocorticosteroids (GCS) according to the degree activity. Group II - 24 patients underwent synchronous intensive therapy: 2–3 sessions of plasmapheresis followed by 1000mg metipred (solumedrol), against GCS disease activity, respectively, III group - 36 patients received conventional therapy with oral administration in dose of Valium 20–40mg/day. Patients of group II marked a complete stabilization of clinical symptoms, decrease in activity, the positive dynamics of cardiovascular manifestations. <h3>Conclusions</h3> Thus, the ineffectiveness of the standard basic therapy in SLE patients should include the feasibility of timely implementation of synchronous pulse therapy, which helps to reduce cardiovascular complications and improves the quality of life of patients. <h3>Disclosure of Interest</h3> None declared
Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study.
Authors: Carole Soussain, Khe Hoang-Xuan, Luc Taillandier, Olivier Casasnovas, Brigitte Dupriez, Anne-Laure Taksin, Bertrand Souleau, Brigitte Kolb, Arnaud Jaccard, Jean-Marc Zini, Sylvain Choquet, Francis Witz, Maud Janvier, Veronique Leblond
Journal: Blood (2006)
The genomic landscape of balanced cytogenetic abnormalities associated with human congenital anomalies
Authors: Claire Redin, Harrison Brand, Ryan L Collins, Tammy Kammin, Elyse Mitchell, Jennelle C Hodge, Carrie Hanscom, Vamsee Pillalamarri, Catarina M Seabra, Mary-Alice Abbott, Omar A Abdul-Rahman, Erika Aberg, Rhett Adley, Sofia L Alcaraz-Estrada, Fowzan S Alkuraya, Yu An, Mary-Anne Anderson, Caroline Antolik, Kwame Anyane-Yeboa, Joan F Atkin, Tina Bartell, Jonathan A Bernstein, Elizabeth Beyer, Ian Blumenthal, Ernie M H F Bongers, Eva H Brilstra, Chester W Brown, Hennie T Brüggenwirth, Bert Callewaert, Colby Chiang, Ken Corning, Helen Cox, Edwin Cuppen, Benjamin B Currall, Tom Cushing, Dezso David, Matthew A Deardorff, Annelies Dheedene, Marc D'Hooghe, Bert B A de Vries, Dawn L Earl, Heather L Ferguson, Heather Fisher, David R FitzPatrick, Pamela Gerrol, Daniela Giachino, Joseph T Glessner, Troy Gliem, Margo Grady, Brett H Graham, Cristin Griffis, Karen W Gripp, Andrea L Gropman, Andrea Hanson-Kahn, David J Harris, Mark A Hayden, Rosamund Hill, Ron Hochstenbach, Jodi D Hoffman, Robert J Hopkin, Monika W Hubshman, A Micheil Innes, Mira Irons, Melita Irving, Jessie C Jacobsen, Sandra Janssens, Tamison Jewett, John P Johnson, Marjolijn C Jongmans, Stephen G Kahler, David A Koolen, Jerome Korzelius, Peter M Kroisel, Yves Lacassie, William Lawless, Emmanuelle Lemyre, Kathleen Leppig, Alex V Levin, Haibo Li, Hong Li, Eric C Liao, Cynthia Lim, Edward J Lose, Diane Lucente, Michael J Macera, Poornima Manavalan, Giorgia Mandrile, Carlo L Marcelis, Lauren Margolin, Tamara Mason, Diane Masser-Frye, Michael W McClellan, Cinthya J Zepeda Mendoza, Björn Menten, Sjors Middelkamp, Liya R Mikami, Emily Moe, Shehla Mohammed, Tarja Mononen, Megan E Mortenson, Graciela Moya, Aggie W Nieuwint, Zehra Ordulu, Sandhya Parkash, Susan P Pauker, Shahrin Pereira, Danielle Perrin, Katy Phelan, Raul E Piña Aguilar, Pino J Poddighe, Giulia Pregno, Salmo Raskin, Linda Reis, William Rhead, Debra Rita, Ivo Renkens, Filip Roelens, Jayla Ruliera, Patrick Rump, Samantha L P Schilit, Ranad Shaheen, Rebecca Sparkes, Erica Spiegel, Blair Stevens, Matthew R Stone, Julia Tagoe, Joseph V Thakuria, Bregje W van Bon, Jiddeke van de Kamp, Ineke van Der Burgt, Ton van Essen, Conny M van Ravenswaaij-Arts, Markus J van Roosmalen, Sarah Vergult, Catharina M L Volker-Touw, Dorothy P Warburton, Matthew J Waterman, Susan Wiley, Anna Wilson, Maria de la Concepcion A Yerena-de Vega, Roberto T Zori, Brynn Levy, Han G Brunner, Nicole de Leeuw, Wigard P Kloosterman, Erik C Thorland, Cynthia C Morton, James F Gusella, Michael E Talkowski
Journal: Nature Genetics (2016)
A randomised controlled trial of CPAP versus non-invasive ventilation for initial treatment of obesity hypoventilation syndrome
Authors: Mark E Howard, Amanda J Piper, Bronwyn Stevens, Anne E Holland, Brendon J Yee, Eli Dabscheck, Duncan Mortimer, Angela T Burge, Daniel Flunt, Catherine Buchan, Linda Rautela, Nicole Sheers, David Hillman, David J Berlowitz
Journal: Thorax (2016)

<h3>Background</h3> Obesity hypoventilation syndrome (OHS) is the most common indication for home ventilation, although the optimal therapy remains unclear, particularly for severe disease. We compared Bi-level and continuous positive airways pressure (Bi-level positive airway pressure (PAP); CPAP) for treatment of severe OHS. <h3>Methods</h3> We conducted a multicentre, parallel, double-blind trial for initial treatment of OHS, with participants randomised to nocturnal Bi-level PAP or CPAP for 3 months. The primary outcome was frequency of treatment failure (hospital admission, persistent ventilatory failure or non-adherence); secondary outcomes included health-related quality of life (HRQoL) and sleepiness. <h3>Results</h3> Sixty participants were randomised; 57 completed follow-up and were included in analysis (mean age 53 years, body mass index 55 kg/m<sup>2</sup>, PaCO<sub>2</sub> 60 mm Hg). There was no difference in treatment failure between groups (Bi-level PAP, 14.8% vs CPAP, 13.3%, p=0.87). Treatment adherence and wake PaCO<sub>2</sub> were similar after 3 months (5.3 hours/night Bi-level PAP, 5.0 hours/night CPAP, p=0.62; PaCO<sub>2</sub> 44.2 and 45.9 mm Hg, respectively, p=0.60). Between-group differences in improvement in sleepiness (Epworth Sleepiness Scale 0.3 (95% CI -2.8, 3.4), p=0.86) and HRQoL (Short Form (SF)36-SF6d 0.025 (95% CI -0.039, 0.088), p=0.45) were not significant. Baseline severity of ventilatory failure (PaCO<sub>2</sub>) was the only significant predictor of persistent ventilatory failure at 3 months (OR 2.3, p=0.03). <h3>Conclusions</h3> In newly diagnosed severe OHS, Bi-level PAP and CPAP resulted in similar improvements in ventilatory failure, HRQoL and adherence. Baseline PaCO<sub>2</sub> predicted persistent ventilatory failure on treatment. Long-term studies are required to determine whether these treatments have different cost-effectiveness or impact on mortality. <h3>Trial registration number</h3> ACTRN12611000874910, results.
THU0307 Repository Corticotropin Injection (RCI) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids: Results from A 44-Week Open-Label Extension Study:
Authors: P. Becker, R. Furie, M. Mitrane, E. Zhao
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> We recently reported results from a pilot 8-week randomized double-blind placebo (PBO)-controlled study of RCI in subjects with persistently active SLE involving skin and/or joints despite moderate dose corticosteroids for ≥4 weeks<sup>a</sup>. Although the primary endpoint of this study (resolution of disease active for SLEDAI rash or arthritis with no worsening of other organ systems by BILAG) was not met, RCI therapy (40U daily or 80U every other day SC) led to improvement in several measures of disease activity, including total hybrid SLEDAI (hSLEDAI), total BILAG, CLASI Activity scores, and Tender and swollen joint count, as compared with PBO. <h3>Objectives</h3> To describe the topline results of a 44-week open-label extension (OLE) of this study of RCI in persistently active SLE. <h3>Methods</h3> 33/38 subjects completed the double-blind phase of the study and opted to enroll in the OLE. Of these 33, 22 had received RCI and 11 PBO during the prior 8 weeks. The dose of RCI could be adjusted beginning at week 9, with the goal of achieving a stable dose (16, 40 or 80U SC, 1–3x/week) to control disease activity no later than Week 28. Beginning at Week 20, investigators were encouraged to taper background prednisone. Disease activity was assessed monthly by hSLEDAI, BILAG, CLASI, Tender &amp; swollen joint counts, and physician9s global assessment (PGA). <h3>Results</h3> 20 subjects completed the OLE, 13/22 from the RCI/RCI and 7/11 from the PBO/RCI groups. No unexpected adverse events were observed. <h3>Conclusions</h3> These data demonstrate that subjects in the RCI/RCI group had a durable response to therapy over 52 weeks, whereas those in the PBO/RCI group experienced improvements in disease activity during the OLE that were generally comparable to the improvements seen with RCI treatment from the blinded phase of the trial. <h3>References</h3> Furie R, Das M, Li D, Smythe S, Mathura E, Becker P. Repository Corticotropin Injection (H.P. Acthar® Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). <h3>Disclosure of Interest</h3> P. Becker Shareholder of: Mallinckrodt Pharmaceuticals Inc, Employee of: Mallinckrodt Pharmaceuticals Inc, R. Furie: None declared, M. Mitrane Consultant for: Mallinckrodt Pharmaceuticals Inc, E. Zhao Employee of: Mallinckrodt Pharmaceuticals Inc
Trends in contact allergy to fragrance mix I in consecutive Danish patients with eczema from 1986 to 2015: a cross-sectional study
Authors: N.H. Bennike, C. Zachariae, J.D. Johansen
Journal: British Journal of Dermatology (2016)

For more than 30 years, fragrance mix I (FMI) has been the most important screening marker for fragrance contact allergy. Meanwhile, governmental and corporate initiatives have been implemented, aimed at reducing sensitization to fragrance allergens, including the single constituents of FMI.To examine trends in contact allergy to FMI from 1986 to 2015 in patients with dermatitis, and to test the hypothesis that sensitization to the fragrance screening marker has decreased within recent years.This was a cross-sectional registry study on patch test results to FMI among consecutively tested patients with dermatitis from a single university clinic across three 10-year periods. From 2006 to 2015, data on eczema location according to the MOAHLFA index (male; occupation; atopic dermatitis; hand; leg; face; age ≥ 40 years), clinical relevance of sensitization, and cosmetic exposures were available.Of 24 168 patients, 7·8% (95% confidence interval 7·4-8·1) were sensitized to FMI. For women, a significant trend (P = 0·004) was observed for an increase in sensitization to FMI across the three decades. From 2011 to 2015, the prevalence of contact allergy to FMI increased significantly for women (8·0% vs. 10·4%, P = 0·002) and men (4·4% vs. 7·3%, P = 0·002) compared with the previous 5-year period. From 2006 to 2015, clinical relevance was established in 78·2% of FMI-positive patients with no differences over time. An increase (28·6% vs. 36·1%, P = 0·05) in FMI-positive patients suffering from facial dermatitis was observed for the period 2011 to 2015 compared with 2006 to 2010.The prevalence of contact allergy to FMI has been increasing in recent years. There was no demonstrable effect of previous preventive initiatives.
Patrick Guy Houghton
Authors: H A G Houghton
Journal: BMJ (2016)

Born into a Birmingham medical family, Patrick Guy Houghton was H D Rolleston scholar at St John’s College, Cambridge, and graduated with first class honours in the medical Tripos in 1968. His training continued at St Thomas’ Hospital in London, where he also spent several evenings each week at concerts or operas. He particularly enjoyed the music of Richard Wagner, whom his great grandfather, Julius Cyriax, had supplied with luxury goods through his London pharmaceutical company and had even persuaded to become godfather to his younger daughter. Guy married a fellow medical student from Cambridge, Jennifer Rumsey, in 1970. After qualifying they spent a year travelling round the world, with Guy gaining international experience of general practice through short term posts in Saskatchewan and New South Wales. He also undertook an early locum in Lambeth with Professor David Morrell, which he found particularly …
Association Between Blood Pressure and Adverse Renal Events in Type 1 Diabetes
Authors: Elaine Ku, Charles E. McCulloch, Michael Mauer, Stephen E. Gitelman, Barbara A. Grimes, Chi-yuan Hsu
Journal: Diabetes Care (2016)

To compare different blood pressure (BP) levels in their association with the risk of renal outcomes in type 1 diabetes and to determine whether an intensive glycemic control strategy modifies this association.
A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma
Authors: Chengsheng Wu, Hai-Feng Zhang, Nidhi Gupta, Abdulraheem Alshareef, Qian Wang, Yung-Hsing Huang, Jamie T. Lewis, Donna N. Douglas, Norman M. Kneteman, Raymond Lai
Journal: Journal of Hematology & Oncology (2016)

We have previously described the existence of two phenotypically distinct cell subsets in ALK-positive anaplastic large cell lymphoma (ALK + ALCL) based on their differential responsiveness to a Sox2 reporter (SRR2), with reporter-responsive (RR) cells being more tumorigenic and chemoresistant than reporter-unresponsive (RU) cells. However, the regulator(s) of RU/RR dichotomy are not identified. In this study, we aim to delineate the key regulator(s) of RU/RR dichotomy.JASPER motif match analysis was used to identify the putative factors binding to SRR2 sequence. SRR2 probe pull-down assay and quantitate real-time PCR were performed to analyze the regulation of Sox2 transcriptional activity by MYC. Methylcellulose colony formation assay, chemoresistance to doxorubicin and mouse xenograft study were performed to investigate the biological functions of MYC. PCR array and western blotting were executed to study related signaling pathways that regulate MYC expression. Immunofluorescence and immunohistochemistry assay were initiated to evaluate the expression of MYC and its correlation with its regulator by chi-square test analysis in human primary tumor cells.We identified MYC as a potential regulator of RU/RR dichotomy. In support of its role, MYC was highly expressed in RR cells compared to RU cells, and inhibition of MYC substantially decreased the Sox2/SRR2 binding, Sox2 transcriptional activity, chemoresistance, and methylcellulose colony formation. In contrast, enforced expression of MYC in RU cells conferred the RR phenotype. The Wnt/β-catenin pathway, a positive regulator of MYC, was highly active in RR but not RU cells. While inhibition of this pathway in RR cells substantially decreased MYC expression and SRR2 reporter activity, experimental activation of this pathway led to the opposite effects in RU cells. Collectively, our results support a model in which a positive feedback loop involving Wnt/β-catenin/MYC and Sox2 contributes to the RR phenotype. In a mouse xenograft model, RU cells stably transfected with MYC showed upregulation of the Wnt/β-catenin/MYC/Sox2 axis and increased tumorigenecity. Correlating with these findings, there was a significant correlation between the expression of active β-catenin and MYC in ALK + ALCL primary tumor cells.A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subset in ALK + ALCL.
THU0188 Efficacy and Safety of Add-on Treatment of Tacrolimus versus Leflunomide in Rheumatoid Arthritis Patients with Inadequate Response To Methotrexate: A 24-Week Double-Blinded Randomized Non-Inferiority Study
Authors: K. Shin, H.J. Baek, Y.M. Kang, S.W. Kang, H.S. Cha, J.B. Jun, S.H. Park, Y.J. Lee, Y.W. Song
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Tacrolimus (TAC) is used as a disease modifying antirheumatic drug (DMARD) in rheumatoid arthritis (RA). Combination of TAC with methotrexate (MTX) has been shown to be effective and safe in RA, yet comparative clinical studies are insufficient to date. <h3>Objectives</h3> To investigate the efficacy and safety of TAC versus leflunomide (LEF) when combined with MTX in RA patients <h3>Methods</h3> The PLATINUM-X study is a 24-week multi-center, double-blinded randomized non-inferior (phase 4) study targeting RA patients with moderate to active disease activity (DAS28(ESR) &gt;3.2) that had a inadequate clinical response to MTX. Patients were randomized into the TAC or LEF (add-on) group. The initial daily dose of TAC and LEF were 1.5 mg and 10 mg, respectively for 4 weeks, then increased to 3 mg, 20 mg until the end of the study. Clinical (DAS28, Korean (K-) HAQ) and laboratory data were obtained at 4, 8, 16, and 24 weeks. The primary endpoint was to compare DAS28 in both groups at 24 weeks. Non-Inferiorly was established if the upper limit of the 95% confidence interval (CI) for DAS28 difference was less than 0.7. Secondary endpoint variables included DAS28, K-HAQ as well as swollen/tender joint counts at each visit. Safety profiles were assessed at each patient9s visit. The per protocol set was used for statistical analysis. <h3>Results</h3> Eighty seven patients were screened in 9 centers, and 75 patents were randomized into 2 groups. Baseline demographics of patients were comparable with baseline DAS28 being 4.54 ± 0.61 and 4.91 ± 1.01 in the TAC and LEF group, respectively. TAC was non-inferior to LEF in terms of reduction of DAS28 at 24 weeks (mean difference -0.0565, CI -0.6513, 0.5384). Improvement of DAS28, K-HAQ throughout each visit was not statistically different between the 2 groups. Yet, reduction in tender joint count was significant in the TAC group compared with LEF (-5.97 ± 4.89 versus -3.08 ± 5.55 at 24 weeks, <i>p</i>=0.0145). There was more numbers of adverse events (AE) or adverse drug reactions in the LEF group (89 in LEF and 64 in TAC); 6 patients presented transaminitis in the LEF group compared with 2 in TAC. <h3>Conclusions</h3> The efficacy of TAC plus MTX is non-inferior to LEF combined the MTX, with reasonable safety profile in RA patients with moderate to active disease activity (cris.nih.go.kr KCT0000781). <h3>References</h3> Tacrolimus in RA patients receiving concomitant MTX. Kremer et al. Arthritis Rheum 2003 Efficacy and safety of tacrolimus in patients with RA. Youcum et al. Arthritis Rheum 2003 <h3>Disclosure of Interest</h3> None declared
AB0822 Hospitalization Trends of Gout and Rheumatoid Arthritis in The United States: A Tale of Two Arthritides
Authors: N. Lu, S.Y. Lim, A. Oza, M. Fisher, S.K. Rai, M.E. Menendez, H.K. Choi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout and rheumatoid arthritis (RA) are the two most common inflammatory <i>arthritides</i>. As hospitalizations for these conditions are known to incur substantial resource use, hospitalization trends and associated costs provide key benchmarks of disease burden. Varying levels of perceived success in their care and changing epidemiology (mainly for gout) may have made a substantial impact over recent years; however, relevant data are scarce. <h3>Objectives</h3> To examine hospitalization trends of gout and rheumatoid arthritis in the US. <h3>Methods</h3> We examined trends in the annual hospitalization rate of gout and RA using the US Nationwide Inpatient Sample (1993–2011). <h3>Results</h3> From 1993 to 2011, the annual hospitalization rate for patients with a principal diagnosis of RA declined by 67% from 13.9 to 4.6 per 100,000 US adults (p&lt;0.001), whereas that for gout doubled from 4.4 to 8.8 per 100,000 US adults (p&lt;0.001), reversing the hospitalization rates between the two conditions over the past two decades. These trends persisted among subgroups by age, sex, race, and geographic region (all p-values&lt;0.001). Approximately 60% of RA admissions and 2% of gout admissions were associated with total joint replacement or other major joint surgeries; the frequency trend of these surgeries paralleled the declining trend in RA hospitalizations (all p-values &lt;0.001). The hospital costs also reflected the hospitalization trends, resulting in $58,003 (2011 USD) per 100,000 US adults for gout and $55,988 per 100,000 US adults for RA in 2011. <h3>Conclusions</h3> These nationally representative inpatient data indicate that both primary hospitalization rates and the inpatient economic burden for gout have increased substantially over the past two decades, whereas those for RA have declined considerably. These trends reflect both suboptimal gout care in addition to its increasing prevalence; these data also provide a key reassuring benchmark for the perceived improvement in RA care, thereby preventing joint replacements. These data support the critical need to improve gout prevention and care. <h3>Acknowledgement</h3> This work was supported in part from a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR065944) <h3>Disclosure of Interest</h3> None declared